Issue of Equity

17 Nov 2009 14:37



Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 259,200 new ordinary shares of 0.1p each ("New Ordinary Shares") pursuant to the exercise of options.

The issue of the New Ordinary Shares is subject to the New Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the New Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 23 November 2009. Following the issue the total number of ordinary shares in issue will be 178,697,988.

- Ends -

For further information:

Cyprotex PLC

Dr. Anthony Baxter  Tel: +44 (0) 1625 505100

Chief Executive Officer

John Dootson 

Chief Financial Officer

iir@cyprotex.com www.cyprotex.com